Nephros (NASDAQ:NEPH) Posts Quarterly Earnings Results

Nephros (NASDAQ:NEPHGet Rating) posted its quarterly earnings results on Wednesday. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07), MarketWatch Earnings reports. Nephros had a negative net margin of 53.75% and a negative return on equity of 35.26%. During the same period last year, the company posted ($0.06) earnings per share.

Shares of NEPH traded down $0.31 during trading hours on Friday, reaching $2.21. The stock had a trading volume of 163,207 shares, compared to its average volume of 13,919. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.70 and a quick ratio of 3.70. Nephros has a 52 week low of $2.20 and a 52 week high of $11.67. The firm has a 50-day moving average of $4.23 and a 200 day moving average of $5.49.

A hedge fund recently raised its stake in Nephros stock. Advisor Group Holdings Inc. boosted its position in shares of Nephros, Inc. (NASDAQ:NEPHGet Rating) by 89.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,674 shares of the company’s stock after purchasing an additional 4,100 shares during the period. Advisor Group Holdings Inc. owned about 0.08% of Nephros worth $38,000 at the end of the most recent reporting period. 55.55% of the stock is owned by institutional investors.

A number of research firms have recently weighed in on NEPH. B. Riley cut their price target on Nephros from $8.00 to $5.25 in a research note on Thursday. Zacks Investment Research downgraded Nephros from a “buy” rating to a “hold” rating in a research note on Wednesday, April 27th.

About Nephros (Get Rating)

Nephros, Inc develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

Further Reading

Earnings History for Nephros (NASDAQ:NEPH)

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with's FREE daily email newsletter.